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Abstract: Autism Spectrum Disorders (ASD) and Attention-Deﬁcit/Hyperactivity Disorder 
(ADHD) are two increasingly prevalent neurodevelopmental disorders. This rise appears to be 
associated with a higher dietary intake of n-6 polyunsaturated fatty acids (PUFAs) and lower of 
n-3 PUFAs. Docosahexaenoic acid (DHA), a key nutritional n-3 PUFA, is crucial for an optimal 
offspring’s neurodevelopment through the last trimester of pregnancy. Recently, lower DHA 
levels have been reported in children with ASD and ADHD. The present review summarizes the 
main research achievements concerning the effect of maternal DHA intake in children 
neurodevelopment, in order to elicit its role in the prevention and mitigation of ASD and ADHD. 
As main finding, a low maternal marine DHA intake seems to negatively affect childhood 
neurodevelopment and increase the risk and the severity of ASD or ADHD. Higher DHA status at 
birth was associated with better childhood neurodevelopmental, but controversial results found 
in prenatal supplementation raised the hypothesis that the benefits of DHA may be influenced 
by other factors as socio-economic background and life-style. In conclusion, an optimal maternal 
consumption of marine products and being breastfeed may promote some neuronal protection 
in offspring, confirming the essential role of DHA as a modifiable risk factor for ASD and ADHD. 
Keywords: Autism Spectrum Disorders; Attention-Deﬁcit/Hyperactivity Disorder; neurodevelopment; 
docosahexaenoic acid; n-3 Polyunsaturated Fatty Acids; maternal seafood intake; pregnancy; lactation.  
 
1. Introduction  
 Autism Spectrum Disorders (ASD) and Attention-Deﬁcit/Hyperactivity Disorder (ADHD) 
are two neurodevelopmental disorders, that evolve as a result of interactions between genetic 
and environmental factors [1, 2].   
 ASD displays deficits in social communication and reciprocal social interaction and 
restricted repetitive activities, behaviors and interests, frequently starting before three years of 
age [3]. In the Fifth Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-
V), the terms Autistic disorder, Asperger disorder, Childhood disintegrative disorder, and 
Pervasive developmental disorder - not otherwise specified are included in ASD, also called 
Pervasive Developmental Disorder [1]. One in each 68 children (1.5%) in United States was 
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affected in 2012, 4.5 times more frequent in boys than girls [4]. Others studies in Europe, Asia, 
and North America reported a prevalence of ASD of 1-2% [5].  
 Although ASD is highly heritable (last estimates 38–54%), environmental factors are 
crucial in its etiology, especially those affecting fetal and early-life development [6]. Advanced 
parental age and birth complications related to ischemia, trauma and hypoxia have shown solid 
links to ASD [2]. Other pregnancy-related factors such as extremely preterm delivery, very low 
birthweight, maternal infection, use of infertility treatments, maternal exposure to 
environmental pollutants or specific medications, maternal obesity and diabetes, have shown a 
less strong, but significant, association with the risk of ASD [2].  
 Despite the growing research interest in ASD, ADHD remains the most studied pediatric 
mental disorder, affecting 5-7% of children and being 3 times more frequent in boys [7, 8]. It is 
defined by ongoing pattern of inattention, problems in controlling impulsive behaviors or be 
overly active, with an onset at 7-12 years of age [1, 7, 8]. Like in ASD, genetic factors play an 
important etiological role, but other external factors, such as alcohol, tobacco or pollutants 
exposure during pregnancy, emotional difficulties, premature delivery, very low birth weight 
and pre- or postnatal brain injury have been shown to contribute to ADHD [9]. 
 The clinical and etiological similarities between the two diseases are remarkable and 
their prevalence identically has increased at an alarming rate [10]. A change to a Western diet, 
characterized by an increase in dietary pro-inflammatory omega-6 polyunsaturated fatty acids 
(n-6 PUFAs), though meat and processed food, and a decrease in anti-inflammatory omega-3 (n-
3 PUFAs), present mainly in seafood, caused a dramatic increase in the n-6 to n-3 PUFA ratio 
from the optimal 1-2:1 of the Paleolithic diet to about 20-30:1 [11]. This change could be one of 
the explanations for the increased prevalence of these diseases, as a high ratio seems to be 
unfavorable for the proper function of central nervous system [12, 13].  
 N-3 PUFAs play a central role in the brain function and structure of the neuronal cell 
membranes, and also in the development of myelin sheath and retina [12]. In particular, 
docosahexaenoic acid (DHA) overcomes 90% of the n-3 PUFAs in the human brain and about 10 
to 20% of total lipids [14], being associated with a number of positive effects on maternal and 
infant health [13]. Higher DHA intake appears to reduce the risk of schizophrenia, bipolar 
disorder, depression, anxiety, and behavior disorders, while suboptimal DHA levels seems to be 
a potentially risk factor for mental illness [15].  
 DHA is quickly incorporated into the retina and brain nervous tissue during the third 
trimester of pregnancy until two years of age [16]. Since the synthesis of DHA in fetus is low, 
maternal DHA intake and status, and placental function, are critical for its supply to the fetus 
[17]. Several observational studies and randomized clinical trials showed that higher prenatal 
levels of DHA might improve pregnancy outcomes, such as birthweight and gestation duration, 
and offspring neurodevelopment [17-20]. However, neurodevelopmental improvements, 
especially for cognitive function, remain controversial and need further clarification [21].   
 PUFA levels in blood are considered consistent biomarkers of their status [22]. Knowing 
that children with ASD and ADHD have lower DHA and lower total n-3 PUFA serum levels 
compared to neurotypical controls, the determination of whether maternal DHA intake alters 
the risk for these diseases is a reasonable and informative next step for research. The present 
paper reviews ASD and ADHD neuroanatomy and physiology, relating them with marine n-3 
PUFAs, especially DHA, from mother’s diet. It also aims to review present knowledge about the 
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impact of DHA levels in prenatal and postnatal neurodevelopment, especially in children at 
higher risk for these diseases, such as preterm and very low birth weight infants. 
 
 
 
2. Neurodevelopment and functionally brain changes in ASD and ADHD 
 
 Several studies indicated that ASD and ADHD have differences in anatomy, function and 
brain connectivity compared to healthy controls, resulting in changes in many 
neurodevelopmental outcomes [10, 23, 24].  
 In patients with ASD, some level of intellectual disability is detected in 70% [25], and 
about 5% to 44% could have a seizure disorder [26]. Anxiety, delays in learning, attention, 
sensory processing and motor activity deficits may also be present [5].  
 An early postnatal brain overgrowth, with an increase in head circumference, is one of 
the most important morphological changes reported in ASD brain [10, 23, 24, 27], described as 
a possible predictor of its diagnosis in infants of high risk families [28]. Anterior temporal region 
and frontal cortex appear to be the most affected [29], highlighting the growth of prefrontal 
cortex – a crucial area in ASD and ADHD physiopathology due to its role in attention, impulse 
control and cognitive function [10]. This overgrowth seems to persist up to 5–6 years of age, 
after which no important volume increase is denoted, probably representing a deviated 
maturational trajectory in ASD brain [30]. However, focal areas of reduced gray matter’s volume, 
such as in fronto-striatal networks, and reduced white matter’s volume in cerebellum and 
cerebral fornices are also described in these children [31].   
 A problem in long-range connectivity is now known as an emerging theory in ASD. 
Dinstein et al. [32] showed that toddlers with Autism displayed a weaker “functional 
connectivity” between brain hemispheres in language areas (including the superior temporal 
gyrus and the inferior frontal cortex), with an abnormal right lateralized processing of language, 
present since the age of 14 months. Other studies found a significantly reduction in the volume 
of corpus callosum, the major white matter bundle in the brain [10, 33]. Overall, ASD patients 
appear to have a reduction in long-range connectivity, but normal or increased short-range 
neuronal connections, which could clarify some of their better processing functions, like visual 
perception or some attention to detail [34]. 
 On the other hand, it has recently been discovered that cerebellum plays a role in 
cognitive functions, making it an important research area for ASD and ADHD [35, 36]. Most of 
the studies found a larger size of cerebellum in ASD children, particularly prominent in its 
posterior lobe [23, 24]. Although vermis has already been reported as smaller or larger 
compared to controls [24, 37], a consistent finding was a significant lower number and size of 
Purkinje cells in postmortem studies [37, 38]. 
 In these patients, there is also a hypoactivation in social brain regions (important for 
facial recognition, empathy, social cognition and behavior), including the inferior frontal gyrus, 
anterior insula, anterior cingulate cortex, interparietal sulcus, fusiform gyrus and amygdala, with 
an enlargement of this last region [39, 40]. However, recent studies pointed out that the 
problem in ASD may not be the social isolation, but a difficulty in the separation of consciousness 
of self and others, as they showed an abnormal activation of the ventromedial prefrontal cortex 
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in non-self performing tasks, while in unaffected children it is only activated in self-referential 
processing [41].  
 Another topic of discussion is the neuroinflammatory phenomenon found in ASD, 
characterized by an activation of microglia, higher pro-inflammatory cytokines brain levels, 
autoantibody generation, and increased blood-brain barrier permeability, which favors the 
migration of leukocytes to brain tissue [6, 42, 43]. Animal models showed that the exposure to 
toxic substances or infections during pregnancy led to an activation of the maternal immune 
system and neuroinflammation in offspring, presenting a negative impact on neurodevelopment 
and subsequently contributing to ASD [44]. 
 Lastly, regarding the neurotransmission changes in ASD, the excitation/inhibition 
imbalance theory stands out [24]. These subjects have high glutamate (excitatory) [45] and low 
Gamma-Aminobutyric Acid (GABA) (inhibitory) blood levels, and a decreased density of GABAA 
receptors [46], with a possible relation between glutamate upregulation and ASD severity [45]. 
The serotonin and dopamine neurotransmission are also altered in these patients. Some of them 
have higher blood levels of serotonin, which can impair language learning and intelligence 
quotient (IQ) level, and promote self-aggression [24]. Other studies pointed out that ASD 
behavior rises up from a dysfunction in the midbrain dopaminergic system [47]. In fact, the use 
of dopamine D2 receptor antagonists showed to be efficient in ameliorating autistic symptoms, 
and this could be due to the mediation of glutamate release via D2, confirming the 
excitation/inhibition imbalance theory [48]. 
 ADHD symptoms, on the other hand, arise from a deficit in executive function, including 
attention and inhibitory control, and working memory [7]. These children are also predisposed 
to present delays in language and motor development, associated with impaired brain activity 
in several neuronal networks [7]. 
 Patients with ADHD seem to experience normal steps of cortical maturation but slower 
than healthy controls [10]. A volume reduction and a cortical thinning in certain brain regions, 
mainly in frontal and prefrontal regions, was found in children with ADHD [49], but the most 
replicable abnormalities are in basal ganglia, being associated with the severity of the symptoms 
[50].   
 Dougherty et al. [10], comparing the structural imaging literature about ASD and ADHD 
brain, found differences in total brain volume, amygdala, and internal capsule. For this last 
alteration, the results in ASD were unclear, while in ADHD were a reduction in Fractional 
Anisotropy (FA), using diffusion tensor images (DTI). However, ASD and ADHD seem to have an 
overlap in the corpus callosum and vermis cerebellar (lower volume in MR images and decreased 
FA in DTI), and superior longitudinal fasciculus (reduced FA) abnormalities, supporting the idea 
that white matter integrity is also affected in ADHD [10, 51]. In ADHD, the amygdala volume has 
already been reported as normal or decreased; so, these authors pointed out that amygdala 
could serve as a marker for discriminating both disorders [10].  
 Finally, ADHD patients have an abnormal neurotransmission with lower levels of 
norepinephrine (particularly in predominantly inattentive ADHD) and dopamine (mainly in 
predominantly hyperactivity-impulsive ADHD) [52]. As these neurotransmitters are associated 
with reward processing, but not with the emotional dysregulation, some authors have suggested 
that serotonin neurotransmission is also altered in ADHD. Serotonin also modulates dopamine 
release and its interaction seems to affect impulsivity; however, further studies are needed to 
confirm its link to ADHD pathology [52]. 
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3. The role of maternal DHA intake in offspring neurodevelopment 
 The human brain growth spurt begins in the third trimester of pregnancy, at which point 
the fetal brain begins to accumulate DHA [53, 54]. This accumulation continues up to the 
postnatal period, being dependent on breastmilk [53].  
 DHA can be obtained from diet or synthesized from α-linolenic acid (ALA, 18:3n-3), a n-
3 PUFA found in walnut, chia, ﬂax seeds, rapeseed and soy [55]. In the liver, ALA suffers a 
desaturation by Δ6-desaturase, an elongation, and another desaturation by Δ5-desaturase to 
finally form Eicosapentaenoic acid (EPA, 20:5n-3). EPA is elongated to 22:5n-3 and 24:5n-3, and 
then, this last compost suffers a new desaturation to 24:6n-3. Finally, in peroxisome, 24:6n-3 is 
β-oxidized to DHA (22:6n-3) [55]. In humans, the ability to convert ALA to DHA is extremely 
limited (less than 0.1 [14]), especially in fetus, making them highly dependent on the transfer of 
maternal DHA through the placenta, influenced by maternal DHA synthesis, mobilization from 
adipose stores, and dietary intake [56]. Furthermore, the desaturase enzymes are not only 
responsible for the conversion of ALA into DHA, but also of Linoleic acid (LA, an n-6 PUFA) into 
Arachidonic acid (ARA), the second most important PUFA, next to DHA, for brain growth [13].  
 DHA, EPA and ARA, also known as Long Chain (LC)-PUFAs, modulate phospholipids 
composition, involved in membrane fluidity, being able to control the functions of enzymes, ion 
channels and receptors, and to regulate neurotransmission [13, 16]. They are also important for 
dendritic growth and neuronal synaptogenesis, and can regulate inflammation [16]. EPA and 
ARA are precursors of eicosanoids (prostaglandins, thromboxanes and leukotrienes), but while 
ARA shows proinflammatory properties, EPA exerts anti-inflammatory effects [53]. On the other 
hand, DHA cannot produce eicosanoid, but it is a source of docosanoids, metabolites that can 
have the ability to inactivate pro-inflammatory and pro-apoptotic signaling [16, 53]. In addition 
to have a general pro-inflammatory effect, higher consumption of n-6 PUFAs increases the 
competition between LA and ALA, as substrates of the enzymes stated above, resulting in a 
lower conversion of ALA to DHA and a lower DHA levels in mothers and fetus [53]. Low DHA 
levels could be harmful for neurodevelopment, especially in preterm infants, who are deprived 
of maternal stores in the third trimester [57]. Overall, an optimal DHA intake during pregnancy 
and postnatal period appears essential, and global recommendations for pregnant and lactating 
women to have a minimum DHA intake of 200 mg/day are being implemented [58].  
 The necessary amount of dietary DHA can be obtained mainly through ﬁsh and other 
seafood intake. However, recent studies indicate that pregnant women do not have enough 
information about the importance of fish consumption, since guidelines emphasizing the health 
risks of methyl-mercury (MeHg) can make them doubtful and unsecure [59]. A large 
observational study showed that children whose mothers consumed lower seafood (<340 
g/week) during pregnancy had increased risk of having lower verbal IQ and lower fine motor 
ability, and suboptimum outcomes for social behavior, communication and social development 
at 6 months to 8 years of age, compared to children whose mothers consumed high seafood 
diets [60]. Currently, although it is known that MeHg is neurotoxic at high levels, the effect in 
neurodevelopment of its exposure in low-level from fish intake remains controversial [61]. This 
effect appears to be influenced by n-6 to n-3 PUFA ratio, suggesting that the balance of this ratio 
may reﬂect the capability of these LC-PUFAs, at higher levels, to increase or protect, respectively, 
inﬂammation induced by MeHg [61]. Furthermore, the beneﬁts of ﬁsh consumption, probably 
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due to its high DHA composition, may overcome or mask the potential MeHg’s adverse effects 
on neurodevelopmental outcomes [61-65].  
 Other authors reported that a high DHA status in umbilical cord blood were associated 
with longer gestation, better visual acuity and higher levels of novelty preference at 6 months, 
and higher cognitive scores at 11 months [66], better motor development and fewer 
internalizing behavior problems at 7 years [67], and higher verbal and full-scale IQ at 8 years 
[68]. Few observational studies reported no association between maternal fish consumption 
[69], DHA in mothers’ red blood cell (RBC) [69, 70] and improvement in neurodevelopmental 
outcomes of healthy children. Note that although these studies were performed in healthy 
children, these symptoms are also present in ASD and some in ADHD. 
 Regarding the randomized clinical trials (RCTs), Mulder et al. [71] showed that infants in 
the placebo group had an increased risk of developing a worse language, an important symptom 
of ASD, than those whose mothers received 400 mg/day of DHA during pregnancy. Two other 
studies, with DHA supplementation alone, reported higher scores on autonomic and motor skills 
scales at 14 days of age, when mothers were supplemented with 600 mg/day of DHA from 12-
20 weeks’ gestation until birth [72], and better problem solving in infants of mothers who 
received 214mg/day of DHA in same period [73]. In Gustafson’s study [72], a more mature 
autonomic function indicates greater flexibility and integrity of the Autonomic Nervous System, 
probably reflecting a better physiological reactivity of the newborn to the environment. 
However, this study had a significantly low rate of completion (78%) and the majority of 
enrollees were non-White, but African American, reporting higher pre-DHA status.  
 In DHA plus EPA prenatal supplementation’s group, four studies found positive results 
[57, 74-79]. For example, in a study with high level of methodological rigor with low attrition, 
Makrides et al. [74] studied preterm infants whose mothers were supplemented with 800mg 
DHA + 100mg EPA per day, from <21 weeks of gestation until birth. These authors found that 
few children in the DHA group had scores indicative of mildly delayed cognitive development, 
evidencing that DHA supplementation is effective at preventing developmental delay in early 
childhood. However, these authors did not find differences between groups in any scales of the 
Behavior Rating Inventory of Executive Function at 4 years of age [78]. Note that although this 
study was not a pure DHA test, since it used fish oil capsules that contains DHA and EPA levels, 
DHA is present in the brain at levels 50 and 200-fold higher than EPA and ALA, respectively [55].   
 Supplementary tables S1 and S2 show the results of observational and RCTs’ studies 
regarding the association between maternal DHA intake during pregnancy and infant 
neurodevelopmental outcomes. Overall, RCTs results from maternal supplementation still 
appear inconclusive and some meta-analyses concluded that maternal n-3 PUFA 
supplementation (DHA or DHA+EPA) had no consistent effect on children neurodevelopment 
[79, 80]. Note that the majority of these studies have important limitations, particularly high 
attrition rates, small sample sizes, and poor statistical design. Moreover, although several 
authors did not generally demonstrate a positive effect of maternal prenatal n-3 PUFA 
supplementation [74-78, 81-83], with few showing a negative effect [84, 85], some found that 
children with better neurodevelopment outcomes individually had higher DHA levels [74-76, 82, 
86]. Furthermore, two of these studies [75, 76], gathering information from 3 European 
countries with high seafood intakes, found that 84.4% of the mothers at the start of 
supplementation had already achieved the recommended DHA intake of 200 mg per day, and 
that, in this group, parental level of education was also relatively high. These authors concluded 
that, possibly, the positive effects of DHA supplementation during prenatal period are less 
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apparent in mothers who already have an optimal dietary DHA supply. The responsiveness to 
prenatal DHA could be related to the characteristics of the specific population groups studied, 
and DHA status could to be a proxy for socio-economic background and healthy life-style factors, 
that may synergically improve brain development [82, 85].  
 It is also important to maintain optimal DHA levels during postnatal period. At this time, 
breastmilk is the main responsible for the amount of DHA in infant´s RBC [87], being dependent 
on maternal DHA consumption [56].  
 DHA from breastmilk seems to be crucial for better language and cognitive function [88-
90], social behavior with fewer attentional symptoms and better global psychosocial health [91, 
92]. Oddy et al. [91] showed that breastfeeding for less than 6 months was an independent 
predictor of mental health problems, such as behavior problems, through childhood and 
adolescence. In the cases of shorter duration of breastfeeding, a maternal fish intake at least 2 
fish times/week could have a protective effect in neurodevelopment [64]. However, other 
studies did not find significant effects of breastfeeding on children’s neurodevelopment [66, 93-
98] (see supplementary table S1). This discrepancy in studies’ results could be due to level of 
control for potential confounders such the heterogeneous composition of breast milk, maternal 
IQ, education level, social economic status, home environment and child care, and/or different 
methods of assessment of outcomes [95, 96]. Women who were more intelligent or better 
educated seem to be more receptive to breastfeeding promotion [96]. 
 However, even if all of breastmilk is consumed by the baby, the DHA intake is only 13-
26 mg/day (0.2–0.4% of total fatty acids), clearly below the rate of uterine accretion of ≈45-50 
mg/kg/day [99]. This amount appears to be sufficient for normal brain development in full-term 
infants, as long as mother consumes optimal amounts of DHA during peri-natal period [100-
103].  
 Some clinical evidence proposed that supplementing both DHA and ARA instead of DHA 
alone is critical to optimal influence on neuronal development of full-term infants [100, 101, 
104] (see supplementary table S3). For example, verbal IQ and visual acuity at 4 years of age was 
comparable between infants receiving both 0,36% DHA and 0,72% ARA during the first 4 months 
of life and breastfed infants, whereas verbal IQ was lower in infants receiving DHA alone [104]. 
Moreover, Drover et al. [100] showed that a DHA-standard concentration of 0.32% was 
adequate to improve cognitive function while higher concentrations (about 0.96% of total fatty 
acids) did not confer additional benefit, and may also contribute to competing and lower ARA 
levels. This could mean that there is possibly an upper limit to the beneﬁts of intaking DHA [100, 
102, 103]. Although these benefits may be due exclusively to ARA supplementation, no study to 
date has investigated the effects of ARA supplementation alone on cognitive development, 
while studies with only DHA-enriched formula have already reported positive effects of this 
supplementation [96]. Other studies, however, did not find short- [102, 105] or long-term [101, 
106] benefits in some cognition measures using LC-PUFA supplements. 
  On the other hand, the standard amount of DHA may not be an adequate approach for 
preterm infants, who appear to be more sensitive to the effects of maternal DHA intake. 
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4. The clinical example of preterm infants, a risk factor for ASD and ADHD 
 
 Preterm infants appear to have deficits in myelin integrity and connectivity of the 
cortical circuits [107, 108], presenting a higher risk for ASD and ADHD, mood, and psychotic 
disorders [109]. Their lower DHA levels may be partially responsible for this impaired 
neurodevelopment [108, 109].   
 In the last years, studies showed that a short-term high DHA dose (0,86-1% of total 
PUFAs) seems to be helpful for an optimal neurodevelopment in preterm infants [110-112], 
mostly in very low birth weight (VLBW) babies (<1500g) [110, 113] (see supplementary table S3). 
For example, Makrides et al. [111] found that a DHA supplementation of about 1% of total 
PUFAs, from day 2 to 4 until term-corrected age, reduced cognitive delay, improved the 
neurological development of girls and was strongly indicative of improved neurodevelopment 
in very preterm infants (≤33 weeks gestation) at 18 months of age, compared to those with a 
standard-DHA diet (0.3% of total fatty acids). In this study, ARA intake was the same in both 
groups (0.6% of total fatty acids). Henriksen et al. [110] found also that a high-DHA 
supplementation (0,86% DHA plus 0,91% ARA) in VLBW infants, during nine weeks, led to better 
capacity to problem solving and recognition memory at 6 months of age. This latter function is 
essential to focus attention, learning and information processing. Lastly, Westerberg et al. [113] 
reported a better-sustained attention at 20 months of age in these high-DHA group, but did not 
find differences in mental and motor development scores between the groups. However, their 
plasma DHA concentration was positively correlated with Bayley Mental Developmental Index, 
showing that this nutrient may be one of the factors that influence the development of VLBW 
babies. Nevertheless, at 8 years of age, these children had no differences in brain 
macrostructure (volume, area and thickness through imaging data), behavioral outcome and 
cognitive functions [114]. Other long-term studies did not report significant benefits in infancy, 
including for executive functions, ADHD and ASD symptoms, and emotional or behavior 
problems [115-118].  
 Overall, some meta-analysis concluded that there is insufficient evidence to recommend 
DHA supplementation in preterm [119], and also in full-term infants [120-122], with respect to 
potential long term neurodevelopmental benefits. Nevertheless, it cannot be ignored that the 
studies stated above showed that a high DHA dose in preterm infants could reduce, in short-
term, the typical symptoms found in ASD and ADHD, diseases that are also characterized by 
lower levels of this nutrient. However, the differential effect of this nutrient on healthy versus 
ASD/ADHD states is one of the most important issues to be addressed [123].  
 
 
5. How can DHA be related to ASD and ADHD? 
 
5.1 Potential mechanistic pathways of DHA in ASD  
 
The conversion of ALA into DHA is insignificant in males while occurring in girls at 9%. 
This could indicate that DHA have an important role in this disorder since ASD is more frequent 
in boys [13]. The higher conversion capacity in females may be due to the importance of 
maintaining optimal DHA levels for their offspring’s development during pre- and postnatal 
period [16]. Actually, several studies reported that children with ASD have lower DHA, EPA and 
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ARA levels and higher total n-6 to n-3 PUFA ratio compared to unaffected children [22]. Parletta 
et al. [124] showed that a worse PUFA profile, especially in relation to this PUFA ratio, is 
associated with clinical severity in children with ASD or ADHD.  
 The low n-3 PUFA levels in ASD can be explained by defects in enzymes involved in the 
DHA and EPA production from ALA, known as fatty acid desaturase (FADS), by deficiencies in its 
process of cell membrane incorporation, or an alteration in its metabolism, for example through 
a possible dysfunction in mitochondrial PUFA oxidation [12, 16, 125]. However, their potential 
biological pathways in ASD are not yet fully understood [125].  
 A deficit of DHA during perinatal period was shown to be associated with a reduction in 
neurogenesis and delays in neuronal migration [126], and it has recently been implicated in 
synaptic plasticity [127] - a new research field in ASD [127, 128]. ASD is also characterized by 
changes in myelination and by an abnormal long-range brain connectivity, and the formation of 
white matter tract appear to be very susceptible to the n-6 to n-3 PUFA ratio [129]. Moreover, 
a low maternal intake of DHA was associated with a decrease in brain-derived neurotrophic 
factor (BDNF), a protein that protect neurons and glia from death [130, 131]. Children with ASD 
have lower BDNF levels, associated with more severe disease [131], and a supplementation with 
DHA could normalize BDNF in some brain areas affected in ASD [132].   
 From a neurochemical point of view, there are studies that point to an effect of DHA 
deficiency on the modulation of GABA-ergic receptor functions, especially in specific GABAA 
receptor subunits [133], or to an interaction between PUFAs and PLA2 (Phospholipase A2), 
present in the plasma membrane [12]. PLA2 is able to inhibit GABAA receptor function and high 
n-6 ARA levels may increase its activation, resulting in increased neuronal excitability [12]. In 
addition, a lower n-3 PUFA intake in rats has shown to reduce dopamine levels in frontal cortex, 
increase basal synaptic release of serotonin and change glutamergic system in offspring female 
rats [134-136]. Then, a DHA supplementation increase synaptic plasticity in hippocampal 
neurons and improved glutamatergic neurotransmission [137]. However, following its 
supplementation, DHA levels increase differently in the various brain regions [12]. As the 
hippocampus and frontal cortex are the brain regions that take the longest time to recover 
normal DHA levels after its prenatal deficit, it may be difficult to restore its concentration in the 
absence of a postnatal dietary intervention [138]. 
 Regarding the problem of systemic immune dysfunction present in up to 60% of autistic 
patients [138], Weiser et al. [139] showed that a high maternal dietary DHA in mouse protect 
offspring from the deleterious effects of maternal infection on ASD behavior symptoms, and 
later on immune system reactivity in adulthood. Furthermore, neuro-inflammation in the 
autistic brain has been reported several times [6, 140, 141], and the increase in the n-6 to n-3 
PUFA ratio is one of the possible reasons for this [12]. In addition to its pro-inflammatory action, 
n-6 PUFA derived prostaglandins may be associated with initiation of preterm labor, with an 
increased risk of ASD in susceptible children [12]. Won et al. [38] found also high autoantibodies 
levels to neuronal and glial molecules in ASD patients, probably linked to a n-6 to n-3 PUFA ratio.  
 Finally, the gut:brain axis was recently pointed as an alternative pathway for the n-3 
PUFA action against ASD [6]. N-3 PUFA deficiency during perinatal period alters intestinal 
microbial balance in offspring, with a reduction in bacterial density and a decrease in the 
proportion of Firmicutes to Bacteroidetes [142]. On the other hand, microbial overgrowth can 
affect the uptake and metabolism of PUFAs and other molecules [143]. As this axis is different 
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among people, its variation in ASD patients may be one of the explanations for the inconsistent 
results in n-3 PUFA supplementation studies.  
 Overall, the majority of these studies underscore the important role of n-3 PUFAs, 
especially DHA, with an optimal n-6 to n-3 PUFA ratio, in the prevention or symptomatic 
improvement of ASD, recently indicating the gut:brain axis as a potential target for intervention 
in ASD. 
 
 
5.2 Potential mechanistic pathways of DHA in ADHD 
 
The study of Stevens et al. [144] was the first to show a link between ADHD and n-3 
PUFAs. These authors found lower DHA and EPA plasma levels in ADHD children, with an overlap 
of PUFA deficiency and ADHD symptoms: thirst, frequent urination, dry skin and hair and nail 
weakness. Recently, a meta-analysis [145] showed that youth with ADHD have lower RBCs DHA, 
EPA and total n-3 PUFAs but not lower levels of total n-6 PUFAs. However, no differences were 
reported in PUFA plasma levels comparing to controls, showing that while RBCs PUFAs are 
strongly correlated with dietary intake of the last month [146], and their brain levels [105], 
plasma levels only reflect its intake in the last days [145].  
Several authors suggested that, as a deficient fetal DHA level results in deficits in white 
matter integrity and in a reduction of functional connectivity in fronto-basal glial circuits (found 
in preterm infants), it could increase the risk of developing ADHD symptoms in childhood [126]. 
The most studied mechanism relating DHA intake to the pathophysiology of ADHD is the 
alteration in cortical dopamine neurotransmission [13, 16]. Dopamine levels and its binding to 
D2 receptors could be reduced, mainly in frontal cortex, in chronic n-3 PUFA deficiencies, 
associated with symptoms similar to those observed in ADHD [147]. 
Other authors have also found a pro-inflammatory status in ADHD, supporting the idea 
that n-3 PUFAs enhance ADHD symptoms by its anti-inflammatory action. For example, Hariri et 
al. [148] showed that 8 weeks of EPA plus DHA supplementation decreased plasma 
inflammatory mediators (C-reactive protein and IL-6) and oxidative stress in children with ADHD, 
although its impact on ADHD symptoms was not evaluated.  
Overall, there is relatively little research regarding the mechanisms of DHA in ADHD, 
compared to ASD information. Recently, the gut:brain axis was also reported to influence ADHD 
symptoms and diagnosis [84]. Indeed, it should be noted that low DHA intake has been 
associated to anxiety disorders [149], a risk factor for ASD and ADHD, while its supplementation 
has shown anxiolytic effects [150]. Therefore, an adequate DHA intake during pregnancy may 
lead to beneﬁcial effects in children with ADHD or ASD also by reducing anxiety symptoms in 
their mothers. 
 
 
6. The role of maternal intake of DHA in the prevalence and risk of ASD and ADHD  
 
6.1. The importance in ASD 
 
Several authors showed the importance of optimal DHA levels in healthy children in 
neurological and motor development, verbal IQ, social behavior, inattention and hyperactivity, 
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both damaged in ASD. However, how maternal intake of DHA additionally affect the 
development of ASD is less clear, and research dedicated to this topic is scarce (see 
supplementary table S4). Recently, Julvez et al. [151] reported that maternal seafood intake 
during pregnancy, particularly large fatty ﬁsh, confer some protection against autism spectrum 
characteristics in offspring at 5 years of age, with a moderate attenuation after adjustment for 
LC-PUFA (including DHA) levels in cord blood. Associations remained positive above the previous 
recommended level of 340 g/week of fish during pregnancy, which appear to confirm the 
importance of optimal maternal DHA levels in preventing or ameliorating ASD symptoms in their 
children. Notably, in this study, cord-blood mercury acted as an important biomarker of seafood 
intake rather than having a neurotoxic association. Lyall et al. [152] also showed that women 
with the lowest total n-3 PUFA intake (the lowest 5% of the distribution) had a 53% increase in 
risk of having a child with ASD as compared with women in the highest 90% of the distribution. 
However, these authors did not find this association when DHA levels were assessed specifically. 
Indeed, no significant associations were found between n-3 PUFA intake in the upper quartiles, 
or maternal fish intake, and ASD risk, suggesting that once the minimum requirements of total 
n-3 PUFA intake for normal development are met, a higher intake may provide little or no 
benefit. Note that a major bias in this study relies on the fact that ASD diagnoses was not 
performed by a clinical evaluation and, therefore, the results should be interpreted with caution. 
Also, since maternal fish consumption had no significant impact on ASD risk, other dietary 
sources of n-3 PUFA may have contributed to the results. In fact, the relation between maternal 
consumption of fish, the main source of DHA and EPA, and the risk of ASD remain controversial, 
with other studies reporting no association between them [151, 153]. However, Julvez et al. 
[151], and Gao et al. [154] found a protective effect of fish intake during or before pregnancy 
against ASD diagnosis, respectively. 
 DHA requirement during pregnancy has to be combined with an optimal postnatal and 
early childhood dietary intake of it, important for cortical circuits’ maturation [12]. If it does not 
happen, it appears to become a risk factor that acts synergistically with other factors in the 
promotion of the pathogenesis of ASD among susceptible children [155].  
 Few studies have investigated the potential protective effects of breastfeeding against 
behavioral problems such as ADHD symptoms, and even fewer on ASD traits. Studies in this area 
found mixed results: while some showed a positive association between breastfeeding and ASD 
[156-160], others did not [161]. For example, Al-Farsi et al. [157] found that, in ASD, there are 
more suboptimal breastfeeding practices comparing to the control group. In agreement, a 
recent meta-analysis provides evidence that breastfeeding may protect against ASD [162]. 
Boucher et al. [159] reported that each additional month (>6 months) of breastfeeding was 
associated with a small improvement in cognitive function and with slightly fewer autistic traits, 
and more mitigated effects were found on ADHD symptoms and attention function. However, 
these authors did not find significant association between breastfeeding duration and the 
occurrence of scores within the clinical range for ASD and ADHD diseases. Finally, Schultz et al. 
[156] found that the use of infant formula without DHA plus ARA supplementation versus 
exclusive breastfeeding was associated with a significant increase in the odds of autistic 
disorder. Nevertheless, DHA is only one of the factors that contribute to the beneficial effects of 
breastmilk in childhood neurodevelopment; other potential molecules, such as oxytocin and 
serum insulin-like growth factor (IGF), are increased in breastmilk and could influence the risk 
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of ASD [162]. These findings may be useful for maternal counseling, especially in cases of risk of 
having ASD.  
 Other studies further indicated that more than a deficit of DHA intake, a higher maternal 
n-6 to n-3 PUFA ratio during pregnancy was associated with a higher number of autism traits in 
offspring [153]. Graff et al. [153] pointed out that these associations were independent of child 
intelligence, suggesting that the PUFAs distribution specifically affects the development of 
autistic traits in addition to general neurodevelopment, but maternal n-3 PUFA status and 
prenatal intake of fish were not associated with child autistic traits. These findings suggest that, 
possibly, the focus of dietary interventions should not only be the increasing of n-3 PUFA intake 
but also the reduction of food intake with high content of n-6 PUFAs.  
 
 
6.2. The importance in ADHD 
 As in ASD, it was proposed that maternal DHA intake during pregnancy and lactation 
influences the neurodevelopment of susceptible children to ADHD [13] (see supplementary 
table S5). 
 Some studies reported that higher maternal DHA levels at birth were associated with 
lower ADHD symptoms, such as inattention in toddlers [163] and hyperactivity/inattention 
during school age [164]. Gale et al. [65] also showed that children whose mothers had eaten 
fatty ﬁsh early in pregnancy, the type of fish richer in DHA and EPA, had a lower risk of 
hyperactivity compared to those whose mothers did not eat fatty ﬁsh. In addition, Sagiv et al. 
[165] found a protective association of ingestion of more than 2 times/week of fish with ADHD-
related behaviors, particularly DSM-IV Impulsive/Hyperactive behaviors. However, other studies 
did not detect any benefits of prenatal seafood intake in attention, once confounders were 
taken into consideration [60].  
  Regarding supplementation studies, there are also mixed results: while some authors 
reported a beneﬁcial effect of prenatal DHA supplementation on measures of attention and 
executive function at preschool age [166, 167], others did not find any association [168]. 
Although these studies addressed healthy population, Ramakrishman et al. [167] showed that 
the same results were present in children with ADHD. 
 Breastfeeding is one of the factors that could be related to ADHD and the prevalence of 
ADHD among patients not fed with breastmilk, but with artificial formula, is significantly higher 
compared to those who are fed with breastmilk [169-172]. Moreover, breastmilk seems to 
prevent ADHD, once breastfeeding of shorter duration appears to be associated with an 
increased internalizing, externalizing, and overall behavioral problems as well as the diagnosis 
of ADHD [169, 171, 172].  
 
 
7. Discussion 
 
 ASD and ADHD arise from interactions between genetic and environmental factors that 
influence neurobiological systems since the prenatal period. It is unlikely that a single 
neuroanatomic or neurophysiological change is responsible for all the pathogenesis of ASD and 
ADHD. An alteration in brain volume is one of the more consistent features of ASD and ADHD, 
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but other problems, such as in myelin integrity, connectivity of the cortical circuits, 
neurotransmission and neuroinflammation, were also described. 
 N-3 PUFAs, especially DHA, are necessary for neurodevelopment. Their tissue 
concentrations in fetal plasma and brain are dependent on maternal diet intake, mainly through 
fish and other seafood. This intake is particularly important during the third trimester of 
pregnancy until the first six months of life. In fact, the current review shows that a low maternal 
intake of fish (or low DHA levels) during pregnancy can affect the neurodevelopment of their 
offspring, resulting in lower cognitive and language function, motor ability, poorer social and 
communication skills, and behavior problems. However, RTCs and other controlled studies have 
not shown the same consistent positive results as found in observational studies. Indeed, 
although the results from maternal supplementation RCTs still appear inconclusive, some 
studies pointed that DHA status in cord and maternal blood are associated with better childhood 
neurodevelopmental outcomes. One possible explanation for this is that, during pregnancy, DHA 
is not the unique factor to intervene in this development, as other factors such as birth weight, 
maternal education, maternal IQ, and smoking may mask the benefits of this intervention. In 
addition, the baseline DHA intake/status is not systematically included in the characterization of 
the study population. As this status could affect the response to changes in DHA intake, this may 
also be one of the reasons for the lack of significant association found in these studies.  
 Besides DHA deficits in prenatal period, an optimal DHA intake during the postnatal 
period may represent a safe and efficacious strategy to mitigate these deficits. In this period, it 
is more important to have an optimal n-6 to n-3 PUFA ratio than ideal levels of DHA. Additionally, 
preterm infants need higher DHA levels than full-term infants. They seem to have a higher risk 
for ASD and ADHD, and a high dose of DHA could reduce the typical symptoms found in ASD and 
ADHD at short-term but not in long-term. Although these results were found in healthy children, 
collectively, these findings provide support for the proposition that reduced perinatal DHA 
accrual in brain may represent a risk factor for ASD and ADHD.  
 Recent studies in ASD found that an optimal maternal consumption of fish and 
breastfeed for 6 months or more, could confer some protection against autism spectrum 
characteristics in offspring, while a higher maternal n-6 to n-3 PUFA ratio seem to be associated 
with higher autism traits in offspring. In addition, the brain-microbiota axis is a future tool for 
finding more effective strategies to prevent or treat ASD, and probably ADHD. These results 
were similar for ADHD, also showing positive findings of maternal DHA intake in the reduction 
of ADHD symptoms, although other studies did not demonstrate this association. Together, it 
suggests that early deficits of DHA in fetal brain may represent a modifiable risk factor for ASD 
and ADHD and could therefore be crucial for early intervention and prevention strategies. 
 In conclusion, DHA-rich food, particularly in pre- and postnatal period, could improve 
the health and well-being of pregnant woman, and reduce the risk for having a child with ASD 
and ADHD, especially in those with a positive family history. Recently, the Food and Drug 
Administration (FDA) and the Environmental Protection Agency (EPA), recommend that 
pregnant women, women who might become pregnant, and breastfeeding mothers eat 2-3 
servings of lower-mercury fish or 8-12 ounces (227 to 340 g) per week, while avoiding fish intake 
that is high in mercury [173, 174]. The novelty comparing to the recommendations of 2014 was 
a creation of three categories of fish: 1) “Best choices” (eat 2-3 times/week; e.g. salmon, tilapia, 
scallop, shrimp); 2) “Good choices” (eat 1 time/week; e.g. halibut, mahi-mahi, snapper) and 3) 
“Fish to avoid”; e.g. swordfish, king mackerel, tilefish.  
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 Finally, DHA supplementation appear to be an alternative to optimize maternal DHA 
levels in women who do not achieve optimal level of fish intake, such as poorly nourished 
mothers or those on vegan diets. N-3 PUFAs supplements and fortified formulas seems to be 
well tolerated. Newberry et al. [80], in a recent systematic review including 21 RCTs studies, 
found that the adverse effects of these supplementation in pregnant and lactating women were 
limited to mild gastrointestinal (GI) symptoms, with no serious adverse events reported. Indeed, 
in preterm and full-term infants, adverse events were also limited to GI symptoms, with most 
serious adverse events related to morbidities associated with prematurity.  
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Supplementary Materials 
Table S1: Observational studies addressing the impact of maternal prenatal fish/DHA intake and breastfeeding in the offspring neurodevelopmental outcomes 
Author N PUFAs measure (time; biological 
samples) 
Food intake assessment Neurodevelopment assessment 
(years) 
 
Results 
Bernard et al. 2017 [97] 
 
 
1080  
mother-child pairs 
(very preterm infants excluded) 
Lactating mothers; colostrum Breastfeeding - mothers’ 
questionnaire 
WPPSI-III 
at 5-6 y 
Longer breastfeeding duration 
associated with higher verbal IQ, 
but not with total and 
performance IQ.  
Exposure to colostrum high in LA 
and low in DHA associated with 
lower IQ (compared to 
colostrum high in DHA or low in 
LA and DHA). 
Girard et al. 2017 [95] 7478  
mother-child pairs 
(full-term infants) 
-- Breastfeeding - mothers’ 
questionnaire 
 
BAS: Pictures similarities scale 
and Naming vocabulary scale; 
SDQ;  
at 3 and 5 y 
Breastfeeding for ≥6 mo 
associated with lower child’s 
hyperactivity.  
No significant differences post-
matching on any outcome. 
Belfort et al. 2016 [94] 1000 
mother-child pairs 
(preterm and full-term infants) 
-- Breastfeeding - mothers’ 
questionnaire 
BRIEF; 
SDQ; 
in mid-childhood 
 
No association between longer 
breastfeeding duration, or 
exclusive breastfeeding, and 
better executive function, 
behavior, or social-emotional 
development in mid-childhood. 
Strain et al. 2015 [61] 1265  
mother-child pairs 
(preterm and full-term infants) 
28 weeks’ gestation; maternal 
serum 
Fish Use Questionnaire BSID-II MDI and PDI; 
MacArthur CDI; 
IBQ-R;  
at 1.7 y 
Higher prenatal DHA levels 
associated with better child’s 
language function, but with 
worse mental development.  
Higher n-6:n-3 ratio associated 
with poorer social 
communication and language 
development. 
No associations between PUFA 
status and IBQ-R scores. 
Lind al. 2014 [98] 1442  
mother-child pairs 
(preterm and full-term infants) 
-- Breastfeeding - mothers’ 
questionnaire 
SDQ  
at 6 y 
No associations between 
breastfeeding for ≥6 mo, and 
exclusively breastfed for ≥3 mo, 
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and better emotional symptoms, 
conduct problems, and total 
difﬁculties, after adjustment. 
Belfort et al. 2013 [88] 1312  
mother-child pairs 
(preterm and full-term infants) 
-- Breastfeeding - mothers’ 
questionnaire 
FFQ, 6 mo pp - estimate prenatal 
fish intake 
 
 
PPVT-III  
at 3 y; 
WRAVMA  
at 3 and 7 y; 
KBIT and WRAML  
at 7 y 
 
 
Longer duration and exclusivity 
of breastfeeding associated with 
better receptive language and 
verbal and non-verbal IQ, with 
no changes in visual motor skills 
and visual memory. 
Higher benefit on visual motor 
ability with ≥2 fish times/week.  
Steer et al. 2013 [68] 2839  
mother-child pairs  
(preterm and full-term infants) 
Throughout pregnancy; 
mothers’ RBCs 
-- WISC  
at 8 y 
Low prenatal DHA levels 
associated with lower IQ.  
Bernard et al. 2013 [70] 
 
1335  
mother-child pairs 
(very preterm infants excluded) 
-- FFQ, days pp - estimate maternal 
prenatal PUFA intake 
 
  
MacArthur CDI  
at 2 y; 
ASQ, PMT 5, a test of design 
copying, and the verbal ﬂuency 
test; 
at 3 y 
No associations between 
prenatal DHA intake and 
neurodevelopment. 
In never-breastfed children: 
Higher maternal n-6:n-3 ratio 
associated with worse CDI, ASQ 
and verbal fluency scores. 
In the group of higher prenatal 
n6:n3 ratio, breastfeeding 
duration had a stronger positive 
effect in language domain.  
Valent et al. 2013 [69] 606  
mother-child pairs 
(full-term infants) 
20-22 or 32 weeks’ gestation; 
maternal serum  
FFQ, 1 mo pp - to estimate 
prenatal fish and PUFA intake. 
 
BSID III  
at 1.5 y  
No associations between 
prenatal fish intake and child 
neurodevelopment. 
No associations between 
maternal DHA, EPA and total n-3 
PUFAs and child 
neurodevelopment.  
Higher n-6:n-3 ratio associated 
with lower language score. 
Quigley et al. 2012 [89] 11 879  
mother-child pairs 
(preterm and full-term infants) 
-- Breastfeeding - mothers’ 
questionnaire 
BAS: Vocabulary, pattern 
construction and picture 
similarities subscales; 
at 5 y  
 
 
Breastfeeding associated with 
better cognitive development, 
mainly in preterm infants.  
Page 3 de 5 
 
Improvements appeared when 
breastfeeding ≥4-6 mo in term 
and ≥2 mo in preterm infants. 
Hayatbakhsh et al. 2012 [92] 4502  
mother-adolescent pairs 
(preterm and full-term infants) 
 
-- Breastfeeding - mothers’ 
questionnaire 
Youth Self Report - CBCL  
at 14 y  
Breastfeeding for ≥4 mo 
associated with fewer 
anxiety/depression symptoms, 
social or attention problems, 
and aggressive/delinquent 
behavior.  
Whitehouse et al. 2011 [90] 1195  
mother-child pairs 
(full-term infants) 
-- Breastfeeding - mothers’ 
questionnaire 
PPVT  
at 10 y 
Breastfeeding for ≥6 mo 
associated with higher language 
outcomes.  
Oddy et al. 2010 [91] 2900  
mother-child pairs 
(preterm and full-term infants) 
 
 
-- Breastfeeding - mothers’ 
questionnaire 
CBCL  
at 2, 6, 8, 10 and 14 y 
Breastfeeding for <6 mo 
associated with higher mental 
health problems, including 
behavior problems, through 
childhood and into adolescence. 
Mendez et al. 2009 [64] 392  
mother-child pairs 
(full-term infants) 
-- FFQ, 3 mo pp - estimate prenatal 
fish intake. 
 
 
MCSA  
at 4 y  
In children breast-fed for <6 mo, 
prenatal fish intake >2–3 
times/week associated with 
higher cognitive and motor 
development (compared to 
intake of ≤1 times/week). 
No association between fish >3 
times/week and better scores.  
In children breast-fed for >6 mo, 
no association between 
maternal fish intake and 
development scores.  
Oken et al. 2008 [62] 25446  
mother-child pairs 
(preterm and full-term infants) 
-- FFQ, 25 weeks’ gestation - 
estimate prenatal fish intake.  
Mothers’ interview - total, 
motor, social and cognitive 
scores at 1.5 y 
Higher prenatal fish intake 
(particularly ≥3 times/week) 
associated with higher 
developmental scores.  
Breastfeeding for >6 mo, 
particularly >10, associated with 
higher developmental scores.  
Oken et al. 2008 [63] 341 
mother-child pairs 
(preterm and full-term infants) 
2nd trimester of pregnancy; 
mothers’ RBCs 
FFQ, 2nd trimester of pregnancy 
- estimate fish, DHA and EPA 
prenatal intake.  
PPVT and WRAVMA  
at 3 y 
Prenatal fish intake >2 
times/week, but not below, 
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 associated with higher language 
and visual motor skills.  
No associations between 
DHA+EPA dietary intake (and 
RBCs levels) and child cognition. 
Gale et al. 2008 [65] 217  
mother-child pairs 
(preterm and full-term infants) 
-- FFQ, 15 and 32 weeks’ gestation 
- estimate prenatal fish intake 
 
SDQ and WASI  
at 9 y  
Eat oily ﬁsh in early or late 
pregnancy associated with lower 
risk of child hyperactivity.  
Eat fish (oily or not) at ≥1 
times/week, in late pregnancy, 
associated with higher verbal IQ.  
Jacobson et al. 2008 [66]  
 
109  
mother-child pairs 
(full-term infants) 
At birth; cord and maternal 
plasma phospholipids. 
1 mo pp; total maternal milk 
lipids 
 
-- TVACT and FTII  
at 0.5 and 0.92 y; 
BSID-II  
at 0.92 y 
Higher cord DHA levels 
associated with longer gestation, 
better visual acuity, higher 
scores of novelty preference, 
and better mental and 
psychomotor scores.  
No associations between DHA 
from maternal milk and 
neurodevelopmental scores.  
Krammer et al. 2008 [93] 13889  
mother-child pairs  
(full-term infants) 
-- Breastfeeding - mothers’ 
questionnaire 
SDQ  
Canadian NLSCY  
at 6.5 y  
 
No association between longer 
breastfeeding duration, or 
exclusive breastfeeding, and 
child social-emotional scores.  
Krabbendam et al. 2007 [67] 393  
mother-child pairs 
(preterm and full-term infants) 
Late gestation; umbilical venous 
plasma phospholipids 
 
-- Dutch version of CBCL  
at 7 y  
Higher DHA status at birth 
associated with lower levels of 
internalizing problem behavior 
(not with externalizing problem).  
Hibbeln et al. 2007 [60] 11875  
mother-child pairs 
(preterm and full-term infants) 
-- FFQ, 32 weeks’ gestation -  
estimate prenatal fish intake.  
 
 
 
 
WISC-III  
at 8 y; 
SDQ  
at 6.75 y; 
Development questionnaire  
at 0.5, 1.5, 2.5 and 3.5 y 
Low prenatal seafood intake 
(<340 g or <3 times/week) 
associated with lower verbal IQ 
and fine motor ability, less pro-
social behavior, and poorer 
social and communication skills.  
Legend: DHA = Docosahexaenoic acid; PUFAs = polyunsaturated fatty acids; Very preterm infants = gestational age <33 weeks; y = years; WPPSI-III = Wechsler Preschool and Primary Scale of Intelligence, Third Edition; 
IQ = Intelligence Quotient; LA = linoleic acid, an n-6 PUFA; BAS = British Abilities Scale; SDQ = Strengths and Difﬁculties Questionnaire; mo = months; BRIEF = Behavior Rating Inventory of Executive Function; BSID II = 
Bayley Scales of Infant Development, Second Edition; MDI = Mental Development Index, in BSID-II; PDI = Psychomotor Developmental Index, in BSID-II; CDI = Communicative Development Inventories; IBQ-R = Infant 
Behavior Record–Revised; FFQ = Food Frequency Questionnaire; pp = postpartum; PPVT = Peabody Picture Vocabulary Test; WRAVMA = Wide-Range Assessment of Visual Motor Abilities; KBIT = Kaufman Brief 
Intelligence Test; WRAML = Wide Range Assessment of Memory and Learning; RBCs = Red Blood Cells; WISC = Wechsler Intelligence Scale for Children; ASQ = Ages and Stages Questionnaire; PMT = Peg Moving Task; 
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BSID-III = Bayley Scales of Infant and Toddler Development, Third Edition; EPA = Eicosapentaenoic acid; CBCL = Child Behavior Checklist; MCSA = McCarthy Scales of Children’s Abilities; WASI = Wechsler Abbreviated 
Scale of Intelligence; TVACT = Teller Visual Acuity Card Test; FTII = Fagan Test of Infant Intelligence; NLSCY = National Longitudinal Survey of Children and Youth. 
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Supplementary Materials 
Table S2: RCTs studies addressing the impact of maternal DHA supplementation during pregnancy and offspring neurodevelopmental outcomes 
Author N Supplementation  
Type; dose (daily) 
Supplementation  
Weeks (mean) 
Neurodevelopment assessment 
(years) 
 
Results 
Ostadrahimi et al. 2017 [86] 
 
150 
Preterm and full-term 
120 mg DHA + 180 mg EPA 24 weeks  
(20 weeks’ gestation - 1 mo pp) 
ASQ  
at 0.3 and 0.5 y 
Supplementation associated 
only with higher communication 
skills at 0.3 y.  
Gould et al. 2017 [84] 543 
Preterm and full-term 
 
800 mg DHA > 19 weeks 
(<21 weeks’ gestation – birth) 
WASI-II; 
FST and ReyCF; 
TEACh; 
RAVL; 
CELF-4; 
WRAT-4; 
Parent report-behavior: Conners 
3 (ADHD) and SDQ; 
at 7 y 
No differences in IQ, language, 
academical abilities, executive 
function or in the diagnosis of 
neurodevelopmental disorders, 
but slightly higher reasoning 
scores in DHA group. 
Supplementation associated 
with more behavior problems 
and executive dysfunction. 
Gould et al. 2016 [85] 2399 
Preterm and full-term 
 
800 mg DHA > 19 weeks 
(<21 weeks’ gestation – birth) 
 
BSID III  
at 1.5 y; 
DAS II  
at 4 y.  
Supplementation associated 
with higher cognitive scores 
when mothers did not complete 
further education, but with 
lower language scores at 1.5 y 
and cognitive development at 4 
y when education was 
completed.  
Smoking nullified the benefits of 
DHA supplementation in 
neurodevelopment. 
Ramakrishnan et al. 2016 [167] 797 
Preterm and full-term 
400 mg DHA 18-22 weeks 
(18-22 weeks’ gestation – birth) 
MSCA; 
BASC-2; 
K-CPT; 
at 5 y  
No differences in cognitive and 
behavioral outcomes.  
Supplementation associated 
with better sustained attention. 
Meldrum et al. 2015 [77] 50 
Full-term 
220 mg DHA + 110 mg EPA 20 weeks 
(20 weeks’ gestation – birth) 
WISC-IV; 
CBCL; 
Beery-Buktenica TVMI; 
No differences in cognition, 
language and fine motor skills. 
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CCC; 
at 12 y 
Higher RBCs’ DHA levels 
associated with higher cognitive 
scores in WISC-IV.  
Hurtado et al. 2015 [83] 110 
Full-term 
392 mg (DHA + EPA) 28 weeks 
(28 weeks’ gestation - 4 mo pp) 
VEPs  
at 0.2 and 0.63 y; 
BSID-II  
at 1 y 
No differences in VEPs, cognitive 
and psychomotor development.  
Ramakrishnan et al. 2015 [81] 730  
Full-term 
400 mg DHA 18-22 weeks 
(18-22 weeks’ gestation – birth) 
BSID-II  
at 1.5 y 
No differences in cognitive, 
motor, or behavioral 
development.  
Gould et al. 2014 [168] 158 
Full-term 
800 mg DHA 20 weeks 
(20 weeks’ gestation – birth) 
Single-object task; 
Multiple-object task; 
Distractibility task;  
WMIC task; 
at 2.25 y. 
No differences in attention, 
working memory and inhibitory 
control. 
No association between cord 
plasma DHA and 
neurodevelopmental outcomes.  
Mulder et al. 2014 [71] 270  
Full-term 
400 mg DHA 24 weeks 
(16 weeks’ gestation – birth) 
TAC  
at 0.17 and 1 y; 
McArthur CDI  
1.17 and 1.5 y; 
BSID-III  
at 1.5 y 
Placebo group associated with 
higher risk of lower language 
development at 1.17 and 1.5 y, 
and lower visual acuity at 0.17 y, 
but not at 1 y. 
Makrides et al. 2014 [78] 646 
Preterm 
800 mg DHA + 100 mg EPA  > 19 weeks 
(<21 weeks’ gestation – birth) 
BRIEF; 
CELF Preschool–2; 
DAS II; 
at 4 y 
No differences in cognition, 
language, and executive 
functioning.  
Gustafson et al. 2013 [72] 52 
Full-term 
600 mg DHA 20-28 weeks 
(12-20 weeks’ gestation – birth) 
NBAS  
at 1-14 days pp 
Supplementation associated 
with higher autonomic and 
motor scores.  
van Goor et al. 2011 [82] 114  
Full-term 
1) 220 mg DHA 
2) 220 mg DHA + 220 mg ARA 
32-38 weeks  
(14-20 weeks’ gestation - 3 mo 
pp) 
BSID-II and Hempel examination 
at 1.5 y 
 
No differences between groups 
in mental and psychomotor 
scores.  
Children with simple MND had 
lower DHA in umbilical venous 
compared to normal children. 
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Escolano-Margarit et al. 2011 
[75] 
270 
Full-term 
500 mg DHA + 150 mg EPA 20 weeks 
(20 weeks’ gestation – birth) 
Hempel examination  
at 4 y; 
Touwen examination  
at 5.5 y 
No differences in 
neurodevelopmental scores. 
Higher prenatal DHA levels in 
fetal and maternal blood, and 
lower maternal ARA:DHA ratio, 
associated with better 
performance on neurological 
examinations.  
Campoy et al. 2011 [76] 315 
Full-term 
500 mg DHA + 150 mg EPA 20 weeks 
(20 weeks’ gestation – birth) 
K-ABC  
at 6.5 y of age 
No differences in cognitive 
function.  
Higher maternal RBCs’ DHA 
levels at delivery associated with 
higher mental processing scores.  
Makrides et al. 2010 [74] 694 
Preterm 
800 mg DHA + 100 mg EPA > 19 weeks 
(<21 weeks’ gestation – birth) 
BSID-III  
at 1.5 y 
No differences in cognitive, 
language and motor 
development.  
Dunstan et al. 2008 [57] 98 
Full-term 
220 mg DHA + 110 mg EPA 20 weeks 
(20 weeks’ gestation – birth) 
GMDS; 
PPVT; 
CBCL; 
at 2.5 y 
Supplementation associated 
with higher scores for eye and 
hand coordination.  
Cord RBCs’ n-3 PUFA levels 
positively correlated with eye 
and hand coordination. 
Judge et al. 2007 [73] 29 
Full-term 
214 mg DHA 16 weeks 
(24 weeks’ gestation – birth) 
2-step problem-solving test: 
support step and search step; 
FTII; 
at 0.75 y 
Supplementation associated 
with better problem solving but 
not with recognition memory.  
Legend: RCTs = Randomized controlled trials; DHA = Docosahexaenoic acid; EPA = Eicosapentaenoic acid; mo = months; pp = postpartum; ASQ = Ages and Stages Questionnaire; mo = months; WASI-II = Wechsler 
Abbreviated Scale of Intelligence, Second Edition; FST = Fruit Stroop Test; ReyCF = Rey Complex Figure; TEACh = Test of Everyday Attention for Children; RAVL = Rey Auditory Verbal Learning Test; CELF = Clinical 
Evaluation of Language Fundamentals; WRAT-4 = Wide Range Achievement Test, Fourth Edition; SDQ = Strengths and Difﬁculties Questionnaire; y = years; BSID-III = Bayley Scales of Infant and Toddler Development, 
Third Edition; DAS II = Differential Ability Scales; MSCA = McCarthy Scales of Children’s Abilities; BASC-2 = Behavioral Assessment System for Children, Second Edition; K-CPT = Conners’ Kiddie Continuous Performance 
Test; WISC-IV = Wechsler Intelligence Scale for Children-IV; CBCL = Child Behavior Checklist; TVMI = Test of Visual-Motor Integration; CCC = Children’s Communication Checklist; RBCs = Red Blood Cells; VEPs = Visual 
Evoked Potentials; BSID-II = Bayley Scales of Infant Development, Second Edition; WMIC = Working Memory and Inhibitory Control; TAC = Teller Acuity Card; CDI = Communicative Developmental Inventory; BRIEF = 
Behavior Rating Inventory of Executive Function; NBAS = Neonatal Behavioral Assessment Scale; ARA = Arachidonic Acid; MND = Minor Neurological Dysfunction; Simple MND = presence of 1 dysfunctional domain; K-
ABC = Kaufman Assessment Battery for Children; GMDS = Griffiths Mental Development Scales; PPVT = Peabody Picture Vocabulary Test; PUFAs = polyunsaturated fatty acids; FTII = Fagan Test of Infant Intelligence.  
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Table S3: RCTs studies addressing the impact of postnatal DHA supplementation in neural development in full-term and preterm infants 
Author N Supplementation  
Type; dose (daily) 
Supplementation length  
Weeks 
Neurodevelopment assessment 
(years) 
 
Results 
Full-term infants 
Willatts et al. 2013 [101] 147 
 
0.21 g/100g DHA + 0.35g/100g 
ARA;  
(Infant formula) 
15-16 weeks 
(<7 days pp - 4 mo pp)  
WPPSI-R; 
Day-Night Test; 
MFFT; 
at 6 y 
No differences in IQ and 
attention control.  
Supplementation associated 
with faster and more efﬁcient 
information processing.  
Colombo et al. 2013 [102] 81 1) 0%DHA (control group) 
2) 0.32% DHA 
3) 0.64% DHA 
4) 0.96% DHA 
All + 0.64% ARA; 
(Infant formula) 
 
48 weeks 
(birth - 12 mo pp) 
BSID-II at 1.5 y; 
MacArthur-Bates CDI at 1.5 y;  
SDRT at 2, 2.5, and 3 y;  
Bear-Dragon Go/No-Go Task at 
3, 3.5, and 4y; 
Stroop tasks and DCCS at 3, 3.5, 
4, and 5 y; 
Tower of Hanoi task at 3, 5, and 
6 y;  
PPVT-III at 5 y; 
WPPSI-III at 6y. 
Supplementation associated 
with better executive function 
and verbal scores at 5 and 6 y.  
Higher supplementation (0.96% 
DHA) associated with less impact 
on neurodevelopment than 0.32 
or 0.64% DHA groups (exception 
Stroop tasks).  
Drover et al. 2011 [100] 131 1) 0% DHA (control group) 
2) 0.32% DHA 
3) 0.64% DHA 
4) 0.96% DHA 
All + 0.64% ARA; 
(Infant formula) 
47-48 weeks 
(1-9 days pp - 12 mo pp) 
BSID-II 
at 1.5 y 
Supplementation associated 
with higher cognitive function.  
No differences between DHA 
groups in mental, psychomotor 
or behavior development.  
Colombo et al. 2011 [103] 122 1) 0% DHA (control group) 
2) 0.32% DHA 
3) 0.64% DHA 
4) 0.96% DHA 
All + 0.64% ARA; 
(Infant formula) 
48 weeks 
(birth - 12 mo pp) 
Visual habituation protocol  
(at 0.3, 0.6 and 0.75 y) 
Supplementation with 0.32% or 
0.64% of DHA associated with 
longer attention activity.  
Supplementation with 0.96% of 
DHA associated with less impact 
on neurodevelopment than 0.32 
and 0.64% groups. 
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Gale et al. 2010 [96] 241 6.8 to 18 mg/100 ml DHA; 
(Infant formula) 
24 weeks 
(birth – 6 mo pp) 
WPPSI-III; 
NEPSY; 
TVPS; 
at 4 y 
Supplementation associated 
with higher total and verbal IQ. 
DHA intake from milk 
(breastmilk plus formula) no 
associated with any 
neurodevelopmental outcome.   
De Jong et al. 2010 [106] 341 0.30% DHA + 0.45% ARA; 
(Infant formula) 
8 weeks 
(birth – 2 mo pp) 
Touwen examination  
at 9 y 
No differences in neurological 
functioning.  
Breastfeeding associated with 
less often ﬁne manipulative 
dysfunction than formula-
feeding. 
Jensen et al. 2010 [166] 160 200 mg DHA; 
(Mothers’ supplementation) 
15-16 weeks 
(5 days pp – 4 mo pp) 
VEP and ETDRS/Bailey-Lovie 
chart; 
Bayley PDI, MSCA, PPT, K-ABC; 
WPPSI-R;  
Sustained Attention scale of the 
Leiter-R; 
At 5 y 
Supplementation associated 
with better sustained attention. 
No differences in visual function 
and other neuropsychological 
domains.  
Pivik et al. 2009 [105] 71 1) 0% DHA or ARA 
2) 0.15% DHA + 0.40% ARA 
3) 0.32% DHA + 0.64% ARA; 
(Infant formula) 
24 weeks 
(birth – 6 mo pp) 
BSID; 
PLS; 
at 0.25 and 0.5 y 
In the 3 groups, developmental 
function and language measures 
were in the normal range. 
No differences in 
neurodevelopmental outcomes. 
Birch et al. 2007 [104] 52 1) 0.35% DHA 
2) 0.36% DHA + 0.72% ARA 
(Infant formula) 
16-17 weeks 
(<5 days pp – 17 weeks pp) 
WPPSI-R; 
ATS protocol and EVA system; 
at 4 y 
DHA+ARA supplementation 
associated with better visual 
acuity and verbal IQ than DHA 
supplementation alone.  
Supplementation only with DHA 
associated with lower verbal IQ 
than breast-fed group. 
No differences between 
DHA+ARA supplementation and 
breast-fed group.  
Preterm infants 
Molloy et al. 2016 [118] 104 
Very preterm infants 
1) 1.0% DHA + 0.6% ARA 
2) 0.35% DHA + 0.6% ARA; 
Day 2-4 pp – estimated due date FrACT; 
Vernier Acuity Test; 
No differences in visual-
processing.  
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(Infant formula) RPST; 
Judgment of line orientation; 
TVPS-3; 
at 7 y.  
Collins et al. 2015 [111] 604 
Very preterm infants 
1) 1.0% DHA + 0.6% ARA 
2) 0.35% DHA + 0.6% ARA 
(Infant formula) 
Day 2-4 pp – estimated due date WASI; 
TEA-Ch;  
RCFT, Fruit Stroop Test, BRIEF; 
RAVLT; 
TVPS-3; 
Parent questionnaires: Conners 
3 (ADHD) and SDQ; 
at 7 y 
No differences in IQ, attention, 
executive function, behavior, 
visual-spatial perceptual skills 
and educational progress.  
No differences in the diagnosis 
of ADHD, ASD or cerebral palsy. 
Almaas et al 2015 [114] 98  
VLBW infants 
0.86% DHA + 0.91% ARA  
(Infant formula) 
9 weeks 
(birth – 9 weeks pp) 
WASI, WISC-III; 
CVLT-II; 
Grooved Pegboard test; 
at 8 y 
No differences in cognitive and 
MRI data on brain volumes or 
cortical surface volume, area 
and thickness.  
Isaacs et al.  2011 [115] 107 0.5 g/100g DHA + 0.1g/100g EPA 
+ 0.04g/100g ARA 
(Infant formula) 
36 weeks 
(birth – 9 mo pp) 
WASI; 
CMS, Word Pairs instrument; 
Neuropsychological Test for 
Children; 
WIAT-II; 
TEA-Ch; 
BADS-C; 
at 10 y 
No differences in IQ, memory, 
language, learning skills, 
academic attainment, attention 
and executive function.  
Westerberg et al. 2011 [113] 92 
VLBW infants 
0.86% DHA + 0.91% ARA  
(Infant formula) 
9 weeks 
(birth – 9 weeks pp) 
BSID MDI; 
ASQ; 
Free-play session test; 
at 1.7 y. 
 
Supplementation associated 
with better attention capacity, 
but no differences in MDI and 
ASQ scores. 
Plasma DHA at delivery 
associated with better sustained 
attention and MDI.  
Smithers et al. 2010 [116] 128 
Very preterm infants 
1) 1.0% DHA + 0.6% ARA 
2) 0.35% DHA + 0.6% ARA 
(Infant formula) 
Day 2-4 pp – estimated due date MacArthur CDI at 2.2 y; 
SDQ and STSC at 3 and 5 y. 
No differences in language 
development and child’s 
behavior.  
Makrides et al. 2009 [111] 657 
Very preterm infants 
1) 1.0% DHA + 0.6% ARA 
2) 0.35% DHA + 0.6% ARA 
(Infant formula) 
Day 2-4 pp – estimated due date BSID  
at 1.5 y 
No differences in mental, 
psychomotor or behavior 
development. 
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For infants weigh <1250g, group 
1 associated with higher mental 
scores, but no statistical 
significant.  
Smithers et al. 2008 [112] 168 
Very preterm infants 
1) 1.0% DHA + 0.6% ARA 
2) 0.35% DHA + 0.6% ARA 
(Infant formula) 
Day 2-4 pp – estimated due date VEP  
at 0.17 and 0.3 y 
No differences in visual acuity at 
0.17 y, but supplementation 
associated with higher visual 
acuity at 0.3 y.  
Henriksen et al. 2008 [110] 105  
VLBW infants 
0.86% DHA + 0.91% ARA 
(Infant formula) 
8 weeks  
(1 week pp – 9 weeks pp) 
ASQ; 
Event-Related Potentials; 
at 0.5 y 
Supplementation associated 
with better problem-solving 
skills and recognition memory.  
Legend: RCTs = Randomized controlled trials; DHA = Docosahexaenoic acid; ARA = Arachidonic Acid; pp = postpartum; WPPSI-R= Wechsler Preschool and Primary Scale of Intelligence –Revised; MFFT = Matching Familiar 
Figures Test; IQ = Intelligence Quotient; BSID-II = Bayley Scales of Infant Development, Second Edition; CDI = Communicative Development Inventories; SDRT = Spatial Delayed Response task; DCCS = Dimensional 
Change Card Sort; PPVT = Peabody Picture Vocabulary Test; NEPSY = Developmental NEuroPSYchological Assessment; TVPS = Test of Visual-Perceptual Skills (non-motor); VEP = Visual evoked potential; PDI = 
Psychomotor Development Index; MSCA = McCarthy Scales of Children’s Abilities; PPT = Purdue Pegboard Test; K-ABC = Kaufman Assessment Battery for Children; Leiter-R = Leiter International Performance Scale-
Revised; PLS = Preschool Language Scales; ATS = Amblyopia Treatment Study; EVA = Electronic Visual Acuity; Very preterm infants = <33 weeks’ gestational age; FrACT = Freiburg Visual Acuity Test; RPST = Randot 
Preschool Stereoacuity Test; TVPS-3 = Test of Visual Perceptual Skills, Third Edition; WASI = Wechsler Abbreviated Scale of Intelligence; TEA-Ch = Test of Everyday Attention for Children; RCFT = Rey Complex Figure 
Test; BRIEF = Behavior Rating Inventory of Executive Function; RAVLT = Rey Auditory Verbal Learning Test; SDQ = Strengths and Difﬁculties Questionnaire; VLBW = Very Low and Extremely Low Birth Weight, <1500g; 
WISC = Wechsler Intelligence Scale for Children; CVLT-II = California Verbal Learning Test II; MRI = Magnetic Resonance Imaging; EPA = Eicosapentaenoic acid; CMS = Children’s Memory Scale; WIAT-II = Wechsler 
Individual Achievement Test, Second Edition; BADS-C = Behavioural Assessment of the Dysexecutive Syndrome for Children; MDI = Mental Development Index; ASQ = Ages and Stages Questionnaire; STSC = Short 
Temperament Scale for Children.  
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Table S4: Overview of the studies addressing the impact of maternal fish and DHA intake and offspring ASD diagnosis 
Author N PUFAs measure (time; biological 
samples) 
Food intake assessment Neurodevelopment assessment 
(years) 
 
Results 
Boucher et al. 2017 [159] 
 
1346 
mother-child pairs 
(term infants) 
-- Breastfeeding - mothers’ 
questionnaire 
 
MSCA; 
K-CPT; 
ADHD: DSM-IV; 
Autistic traits:  CAST; 
at 4 y 
 
Longer breastfeeding duration 
(for each additional month) 
associated with better cognitive 
outcomes and fewer autistic 
traits. More mitigated effects for 
ADHD symptoms.  
No association between 
breastfeeding duration and ASD 
and ADHD in the clinical range*. 
Julvez et al. 2016 [151] 1892 
mother-child pairs 
(term infants) 
 
At birth; cord-blood 
 
FFQ at 10-13 and 28-32 weeks’ 
gestation 
BSID  
at 1.17 y; 
MSCA  
at 5 y;  
Autistic traits: CAST  
at 5 y 
 
Maternal seafood intake, 
particularly within the highest 
quantile (>238 g/week), 
associated with moderate child 
neurodevelopment benefits, 
with a better cognition and 
fewer autistic traits. 
Part of the associations reduced 
by adjustments for PUFA levels. 
Graff et al. 2016 [153] 4624  
mother-child pairs 
(preterm and term infants) 
 
Midpregnancy (median: 20.6 
weeks’ gestation); maternal 
plasma 
FFQ, early pregnancy (median, 
13.8 weeks) and at 1.2 y pp 
Autistic traits: SRS and CBCL  
at 6 y 
Lower prenatal n-3:n-6 PUFA 
ratio associated with more 
autistic traits. 
No association between 
maternal n-3 PUFA levels (or 
prenatal dietary fish intake) and 
child autistic traits.  
Gao et al. 2016 [154] 926  
mother-child pairs 
-- Parental questionnaire: diet 
from 0.5 y before pregnancy to 
birth. 
ASD: DSM-IV and CARS score ≥ 
30. 
Parental fish intake before 
pregnancy associated with lower 
risk of child autism. 
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Husk et al. 2015 [161] 37901 
mother-child pairs 
(preterm and term infants) 
-- Breastfeeding - mothers’ 
questionnaire 
ASD: parental report and DSM-IV No association between any 
measure of breastfeeding 
history and ASD. 
Shafai et al. 2014 [158] 145 
mother-child pairs 
 
-- Breastfeeding - mothers’ 
questionnaire 
ASD: parental report Longer breastfeeding duration, 
especially ≥12 mo, associated 
with less ASD diagnosis.  
Lack of breastfeeding associated 
with higher risk of having ASD in 
genetically susceptible children. 
Lyall et al. 2013 [152] 18045 
mother-child pairs 
 
-- FFQ, during pregnancy or until 
1–2 y pp  
ASD: parental report 
Validation: ADI-R by phone and 
SRS.  
Very low maternal n-3 PUFA 
intake associated with higher 
risk of ASD (RR=1.53). 
No associations between 
maternal ﬁsh intake and ASD. 
Al-Farsi et al. 2012 [157] 204 
mother-child pairs 
 
-- Breastfeeding - mothers’ 
questionnaire 
ASD: DSM-IV-R Late initiation of breastfeeding, 
non-intake of colostrum, 
prelacteal feeding**, and 
formula-feeding associated with 
higher prevalence of ASD.  
Longer exclusive breastfeeding 
and continued breastfeeding 
during the first 2 y associated 
with lower ASD risk.  
Schultz et al. 2006 [156] 984 
mother-child pairs 
-- Breastfeeding - mothers’ 
questionnaire 
ASD: parental report using 
online internet survey 
 
Lack of breastfeeding associated 
with higher risk for AD 
(OR=2.48), compared to 
breastfeeding for > 6 mo. 
Infant formula without DHA and 
ARA associated with higher risk 
for AD (OR=4.41), compared to 
exclusive breastfeeding. 
Legend: DHA = Docosahexaenoic acid; MSCA = McCarthy Scales of Children’s Abilities; K-CPT = Kiddie Continuous Performance Test; DSM-IV = Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; CAST 
= Childhood Asperger Syndrome Test; FFQ = Food Frequency Questionnaire; BSID = Bayley Scales of Infant Development; PUFAs = polyunsaturated fatty acids; pp = postpartum; SRS = Social Responsiveness Scale; CBCL 
= Child Behavior Checklist; CARS = Childhood Autism Rating Scale; ADI-R = Autism Diagnostic Interview-Revised; AD = Autistic Disorder.  
* ADHD in the clinical range estimated by recording ratings of options 0 and 1 as “symptom absent, and ratings of 2 and 3 as “symptom present”, and using the DSM-IV criteria for ADHD (≥ six symptoms within a single 
category). For ASD: Score in the clinical range (≥ 15).  
** Prelacteal feeds: food or liquid received before the initiation of breastfeeding. 
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Table S5: Overview of the studies addressing the impact of maternal fish and DHA intake and offspring ADHD diagnosis 
Author N PUFAs measure (time; biological 
samples) 
Food intake assessment Neurodevelopment assessment 
(years) 
 
Results 
Stadler et al. 2016 [172] 474 
mother-child pairs 
-- Breastfeeding - mothers’ 
questionnaire 
ADHD: DSM-V  
at 7-13 y 
Breastfeeding <6 mo associated 
with higher prevalence of ADHD. 
Park et al. 2014 [171] 874 
mother-child pairs 
-- Breastfeeding - mothers’ 
questionnaire 
 
ADHD: DISC-IV; 
CBCL; 
KEDI-WISC; 
at 8-11 y 
Lack of breastfeeding associated 
with higher internalizing, 
externalizing and other 
behavioral problems, lower 
child’s IQ, and increased ADHD 
prevalence.  
Groen et al. 2013 [170] 1739 
mother-child pairs 
 
-- Breastfeeding - mothers’ 
questionnaire 
 
CBCL  
at 3, 7, 10 and 12 y; 
RAKIT  
at 5, 7 and 10 y; 
WISC-R and WISC-R-III  
at 10 and 12 y; 
CITO  
at 12 y 
Breastfeeding associated with 
higher educational attainment, 
less overactive behavior and a 
trend toward higher IQ.  
Mimouni-Bloch et al. 2013 [169] 159 
mother-child pairs 
 
-- Breastfeeding - mothers’ 
questionnaire 
 
ADHD: clinical diagnosis not 
specified  
at 6-12 y 
ADHD associated with less 
frequent breastfeeding at 3 and 
6 mo.  
Sagic et al. 2012 [165] 515 
mother-child pairs 
 
-- FFQ, days after birth - estimate 
prenatal fish intake. 
ADHD symptoms: CRS-T and 
DSM-IV; 
WISC-III; 
CPT; 
at 8 y 
Fish intake >2 times/week 
associated with better ADHD-
related behaviors, mainly 
Impulsive/Hyperactive 
behaviors. 
Maternal fish intake associated 
with higher cognitive scores. 
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Kohlboeck et al. 2011 [164] 416 
mother-child pairs 
(term infants) 
At birth; cord blood serum 
 
-- SDQ  
at 10 y 
Higher cord blood DHA 
associated with lower 
hyperactivity/inattention scores 
and fewer emotional symptoms. 
Kannass et al. 2009 [163] 45 
mother-child pairs 
 
At birth; Maternal RBCs 
phospholipids 
-- Free-play tasks, including the 
multiple-object task 
at 1 and 1,5 y 
Higher maternal DHA status at 
birth associated with higher 
attention, and lower 
distractibility.  
Julvez et al. 2007 [160] 500 
mother-child pairs 
 
-- Breastfeeding - mothers’ 
questionnaire 
ADHD: DSM-IV; 
MSCA; 
CPSCS; 
at 4 y 
 
 
Breastfeeding > 3 mo associated 
with fewer attention and 
hyperactivity symptoms and 
better socio-behavioural 
outcomes.  
Breastfeeding > 5 mo associated 
with higher executive function 
scores.   
Legend: DHA = Docosahexaenoic acid; FFQ = Food Frequency Questionnaire; DSM= Diagnostic and Statistical Manual of Mental Disorders; DISC-IV = Diagnosis Interview Schedule for Children Version-IV; CBCL = Child 
Behavior Checklist; KEDI-WISC = Korean Educational Development Institute’s-Wechsler Intelligence Scales for Children; IQ = Intelligence Quotient; RAKIT = Revised Amsterdamse Kinder Intelligentie children; WISC-R = 
Wechsler Intelligence Scales for Children – Revised; CITO = CITO-elementary Test for Educational attainment; CRS-T = Conners’ Rating Scale-Teachers; CPT = Continuous Performance Test; SDQ = Strength and Difﬁculties 
Questionnaire; RBCs = Red Blood Cells; CPSCS = California Preschool Social Competence Scale. 
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Preparation of a Manuscript 
General Considerations 
• Research manuscripts should comprise:  
o Front matter: Title, Author list, Affiliations, Abstract, Keywords; 
o Research manuscript sections: Introduction, Materials and Methods, Results, Discussion, Conclusions 
(optional); 
o Back matter: Supplementary Materials, Acknowledgments, Author Contributions, Conflicts of Interest, 
References. 
• Review manuscripts should comprise the front matter, literature review sections and the back matter. 
The template file can also be used to prepare the front and back matter of your review manuscript. It 
is not necessary to follow the remaining structure. Structured reviews and meta-analyses should use 
the same structure as research articles and ensure they conform to the PRISMA guidelines. 
• Case reports should include a succinct introduction about the general medical condition or relevant 
symptoms that will be discussed in the case report; the case presentation including all of the relevant 
de-identified demographic and descriptive information about the patient(s), and a description of the 
symptoms, diagnosis, treatment, and outcome; a discussion providing context and any necessary 
explanation of specific treatment decisions; a conclusion briefly outlining the take-home message and 
the lessons learned. 
• Abstract graphic: Authors are encouraged to provide a graphical abstract as a self-explanatory image 
to appear alongside with the text abstract in the Table of Contents. Figures should be a high quality 
image in any common image format. Note that images displayed online will be up to 11 by 9 cm on 
screen and the figure should be clear at this size. 
• Abbreviations should be defined in parentheses the first time they appear in the abstract, main text, 
and in figure or table captions. 
• SI Units (International System of Units) should be used. Imperial, US customary and other units should 
be converted to SI units whenever possible. 
• Accession numbers of RNA, DNA and protein sequences used in the manuscript should be provided 
in the Materials and Methods section. Please also see the section on Deposition of Sequences and of 
Expression Data.  
• Equations: If you are using Word, please use either the Microsoft Equation Editor or the MathType 
add-on. Equations should be editable by the editorial office and not appear in a picture format. 
• Research Data and supplementary materials: Note that publication of your manuscript implies that 
you must make all materials, data, and protocols associated with the publication available to readers. 
Please disclose at the submission stage any restrictions on the availability of materials or information. 
Read the information about Supplementary Materials and Data Deposit for additional guidelines. 
• Preregistration: Where authors have preregistered studies or analysis plans, links to the 
preregistration must be provided in the manuscript. 
• Guidelines and standards: MDPI follows standards and guidelines for certain types of research. See 
http://www.mdpi.com/editorial_process for further information. 
 
Front Matter 
These sections should appear in all manuscript types  
• Title: The title of your manuscript should be concise, specific and relevant. It should identify if the 
study reports (human or animal) trial data, or is a systematic review, meta-analysis or replication 
study. When gene or protein names are included, the abbreviated name rather than full name should 
be used.  
• Author List and Affiliations: Authors' full first and last names must be provided. The initials of any 
middle names can be added. The PubMed/MEDLINE standard format is used for affiliations: complete 
address information including city, zip code, state/province, country, and all email addresses. At least 
one author should be designated as corresponding author, and his or her email address and other 
details should be included at the end of the affiliation section. Please read the criteria to qualify for 
authorship. 
• Abstract: The abstract should be a total of about 200 words maximum. The abstract should be a single 
paragraph and should follow the style of structured abstracts, but without headings: 1) Background: 
Place the question addressed in a broad context and highlight the purpose of the study; 2) Methods: 
Describe briefly the main methods or treatments applied. Include any relevant preregistration 
numbers, and species and strains of any animals used. 3) Results: Summarize the article's main 
findings; and 4) Conclusion: Indicate the main conclusions or interpretations. The abstract should be 
an objective representation of the article: it must not contain results which are not presented and 
substantiated in the main text and should not exaggerate the main conclusions. 
• Keywords: Three to ten pertinent keywords need to be added after the abstract. We recommend that 
the keywords are specific to the article, yet reasonably common within the subject discipline. 
 
Back Matter 
• Supplementary Materials: Describe any supplementary material published online alongside the 
manuscript (figure, tables, video, spreadsheets, etc.). Please indicate the name and title of each 
element as follows Figure S1: title, Table S1: title, etc. 
• Acknowledgments: All sources of funding of the study should be disclosed. Clearly indicate grants that 
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